RT Journal Article SR Electronic T1 Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide with implications for heart and kidney disorders JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.11.08.22282073 DO 10.1101/2022.11.08.22282073 A1 Andrikopoulos, Petros A1 Aron-Wisnewsky, Judith A1 Chakaroun, Rima A1 Myridakis, Antonis A1 Forslund, Sofia K. A1 Nielsen, Trine A1 Adriouch, Solia A1 Holmes, Bridget A1 Chilloux, Julien A1 Vieira-Silva, Sara A1 Falony, Gwen A1 Salem, Joe-Elie A1 Andreelli, Fabrizio A1 Belda, Eugeni A1 Kieswich, Julius A1 Chechi, Kanta A1 Puig-Castellvi, Francesc A1 Chevalier, Mickael A1 Le Chatelier, Emmanuelle A1 Olanipekun, Michael T. A1 Hoyles, Lesley A1 Alves, Renato A1 Helft, Gerard A1 Isnard, Richard A1 Køber, Lars A1 Pedro Coelho, Luis A1 Rouault, Christine A1 Gauguier, Dominique A1 Gøtze, Jens Peter A1 Prifti, Edi A1 , A1 Zucker, Jean-Daniel A1 Bäckhed, Fredrik A1 Vestergaard, Henrik A1 Hansen, Torben A1 Oppert, Jean-Michel A1 Blüher, Matthias A1 Nielsen, Jens A1 Raes, Jeroen A1 Bork, Peer A1 Yaqoob, Muhammad M. A1 Stumvoll, Michael A1 Pedersen, Oluf A1 Ehrlich, S. Dusko A1 Clément, Karine A1 Dumas, Marc-Emmanuel YR 2022 UL http://medrxiv.org/content/early/2022/11/08/2022.11.08.22282073.abstract AB Objectives The host-microbiota co-metabolite trimethylamine N-oxide (TMAO) is linked to increased thrombotic and cardiovascular risks. Here we, sought to i) characterize which host variables contribute to fasting serum TMAO levels in real-life settings ii) identify potential actionable therapeutic means related to circulating TMAO.Design We applied “explainable” machine learning, univariate-, multivariate- and mediation analyses of fasting plasma TMAO concentration and a multitude of bioclinical phenotypes in 1,741 adult Europeans of the MetaCardis study. We expanded and validated our epidemiological findings in mechanistic studies in human renal fibroblasts and a murine model of kidney fibrosis following TMAO exposure.Results Next to age, kidney function was the primary variable predicting circulating TMAO in MetaCardis, with microbiota composition and diet playing minor, albeit significant roles. Mediation analysis revealed a causal relationship between TMAO and kidney function decline that strengthened at more severe stages of cardiometabolic disease. We corroborated our findings in preclinical models where TMAO exposure augmented conversion of human renal fibroblasts into myofibroblasts and increased kidney scarring in vivo. Mechanistically, TMAO aggravated kidney fibrosis due to ERK1/2 hyperactivation synergistically with TGF-β1 signaling. Consistent with our findings, patients receiving next-generation glucose-lowering drugs with reno-protective properties, had significantly lower circulating TMAO when compared to propensity-score matched control individuals.Conclusion After age, kidney function is the major determinant of fasting circulating TMAO in adults. Our findings of lower TMAO levels in individuals medicated with reno-protective anti-diabetic drugs suggests a clinically actionable intervention for decreasing TMAO-associated excess cardiovascular risk that merits urgent investigation in human trials.Data availability statement Raw shotgun sequencing data that support the findings of this study have been deposited in the European Nucleotide Archive with accession codes PRJEB37249, PRJEB38742, PRJEB41311 and PRJEB46098. Serum NMR and urine NMR metabolome data have been uploaded to Metabolights with accession number MTBLS3429; serum GC-MS and isotopically quantified serum metabolites (UPLC–MS/MS) are available from MassIVE with accession numbers MSV000088042 and MSV000088043, respectively.Competing Interest StatementKC is a consultant for Danone Research, Ysopia and CONFO therapeutics for work not associated with this study. KC held a collaborative research contract with Danone Research in the context of MetaCardis project. FB is a shareholder of Implexion pharma AB. MB received lecture and/or consultancy fees from AstraZeneca, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis and Sanofi.Funding StatementThis work was supported by European Union's Seventh Framework Program for research, technological development and demonstration under grant agreement HEALTH-F4-2012-305312 (METACARDIS). Assistance Publique-Hôpitaux de Paris (AP-HP) is the promoter of the clinical investigation (MetaCardis). Partial funding supports to K.C. and J.A.-W were also obtained from Leducq Foundation (TransAtlantic grant), SFN (Société Française de Nutrition), F-CRIN-FORCE network for support, INSERM via ITMO and JPI-Microdiet study and Novo Nordisk foundation (Jacobaus prize). S.K.F. received support from Deutsche Forschungsgesellschaft SFB1365 ("RENOPROTECTION") and SFB1470: "HFpEF". P.A. is an ISSF Fellow supported by the Wellcome Trust and Imperial College London (Grant No. ISSF 204834/Z/16/Z). K.Ch. is an ISSF Fellow supported by the Wellcome Trust and Imperial College London (Grant No. ISSF 204834/Z/16/Z). M.-E.D. is supported by the NIHR Imperial Biomedical Research Centre, GutsUK, Diabetes UK and by grants from the French National Research Agency (ANR-10-LABX-46, European Genomics Institute for Diabetes), from the National Center for Diabetes Precision Medicine - PreciDIAB, which is jointly supported by the French National Agency for Research (ANR-18-IBHU-0001), by the European Union (FEDER), by the Hauts-de-France Regional Council (Agreement 20001891/NP0025517) and by the European Metropolis of Lille (MEL, Agreement 2019_ESR_11) and by Isite ULNE (R-002-20-TALENT-DUMAS), also jointly funded by ANR (ANR16-IDEX-0004-ULNE), the Hauts-de-France Regional Council (20002845) and by the European Metropolis of Lille (MEL). This research was conducted within the context of the CNRS-Imperial International Research Project METABO-LIC. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research institution at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Ethics Committee CPP lle-de France, the Ethical Committees of the Capital Region of Denmark (H-3-2013-145) and Ethics Committee at the Medical Faculty at the University of Leipzig (047-13-28012013).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw shotgun sequencing data that support the findings of this study have been deposited in the European Nucleotide Archive with accession codes PRJEB37249, PRJEB38742, PRJEB41311 and PRJEB46098. Serum NMR and urine NMR metabolome data have been uploaded to Metabolights with accession number MTBLS3429; serum GC-MS and isotopically quantified serum metabolites (UPLC-MS/MS) are available from MassIVE with accession numbers MSV000088042 and MSV000088043, respectively.